Real-world implementation of non-endoscopic triage testing for Barrett's oesophagus during COVID-19.

ABSTRACT:

Background

The Coronavirus pandemic (COVID-19) curtailed endoscopy services, adding to diagnostic backlogs. Building on trial evidence for a non-endoscopic oesophageal cell collection device coupled with biomarkers (Cytosponge), an implementation pilot was launched for patients on waiting lists for reflux and Barrett's oesophagus surveillance.

Aims

(i) To review reflux referral patterns and Barrett's surveillance practices. (ii) To evaluate the range of Cytosponge findings and impact on endoscopy services.

Design and methods

Cytosponge data from centralized laboratory processing (trefoil factor 3 (TFF3) for intestinal metaplasia (IM), haematoxylin & eosin for cellular atypia and p53 for dysplasia) over a 2-year period were included.

Results

A total of 10 577 pr

SUBMITTER: Landy R 

PROVIDER: S-EPMC10497181 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature